And we also assessed the expression levels of a panel of antigen‐presenting machinery genes (B2m, Erap1, Tapbp, Tap2, Tap1) and lysosome‐related genes (Gns, Lamp1, Clcn7, Naglu, Scpep1) in tumor cells following I3A treatment. Q‐PCR analysis indicated significant upregulation of tumor antigen presentation‐related gene expression levels in response to I3A treatment, potentially contributing to the enhanced tumor antigenicity (Figure 2G,H, Figure S2H,I, Supporting Information). This evidence concerns the gene TAP2 and neoplasm.